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Background: Huntington Disease (HD) is a neurodegenerative disorder resulting from the expansion of
polyglutamine stretch in the huntingtin protein (Htt). Mutant HTT (mHtt) leads to progressive impairment of several
molecular pathways that have been linked to disease pathogenesis. Defects in the production of a number of
neurotrophic factors have been described as important determinants contributing to the development of HD. We
have previously demonstrated that production of transforming growth factor-β1 (TGF-β1) is also deregulated in HD.
Peripheral levels of TGF-β1 were markedly reduced early in the disease and returned to normal levels with disease
severity. However, the cause and the biochemical origin of such abnormalities are still unclear.
Results: We report here that the abnormal production of peripheral TGF-β1 depends on the changes in the
percentage of TGF-β1-producing macrophages along disease course. Variation in the number of TGF-β1-producing
macrophages resulted from differential activation state of the same cells, which displayed phenotypic and functional
heterogeneity throughout the clinical course of HD. We further demonstrated that, similar to the periphery, the number
of TGF-β1-immunoreactive cells in human post-mortem brain with HD, varied with neuropathological changes.
Conclusions: Our data indicate that reduced bioavailability of TGF-β1 in the serum of HD subjects is attributable to
the variation of the number of TGF-β1-producing macrophages. Macrophages display a differential ability to produce
TGF-β1, which reflects diversity in cells polarization throughout the disease course. Besides elucidating the biochemical
origin of TGF-β1 fluctuations in HD, our study highlights an interesting parallelism between periphery and central
compartment and underlines the potential of TGF-β1 as a possible indicator suitable for prediction of disease onset
in HD.
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Huntington disease (HD) is a progressive neurodegener-
ative disorder, caused by an expanded CAG repeat
within HTT gene encoding an abnormal long polygluta-
mine (polyQ) stretch in the huntingtin protein (Htt).
Elongated polyQ tract contributes to either gain-of-toxic
function of Htt or loss-of-function of many other pro-
teins, resulting in a broad array of cell dysfunctions
within and out the nervous system [1]. In the brain, pro-
gressive striatal atrophy, degeneration of cortico-striatal* Correspondence: ferdinando.squitieri@lirh.it
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reproduction in any medium, provided the orfibers and glial activation are characteristic features of
HD and represent early events in the disease course. Al-
though the disease has traditionally been described as a
disorder purely of the brain, abnormalities outside the
central nervous system (CNS) are commonly found in
HD [2]. Mutant huntingtin (mHtt) has been widely de-
scribed to be highly expressed in immune cells which
are becoming increasingly interesting in the study of
neurodegenerative disorders as well as in the pathogenesis
of the disease [3,4]. Defective regulation of growth factors,
including brain-derived neurotrophic factor (BDNF) [5]
and glial-derived neurotrophic factor (GDNF) [6] has been
reported to affect CNS function [7] and to contribute toal Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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forming growth factor-β1 (TGF-β1), a growth factor with
established neuroprotective function and powerful anti-
inflammatory properties [9] is also reported altered in HD
[10]. Levels of TGF-β1 dynamically vary with HD develop-
ment in both central and peripheral districts [10]. TGF-β1
plays a critical role in the regulation of several physiological
processes including cell cycle control, cell differentiation
and immune functions [11]. In addition to that, TGF-β1
contributes to maintain neuronal survival and integrity of
CNS and regulates microglia activation [12]. Perturbations
of the TGF-β1 signaling are involved in many neurodegen-
erative disorders [13]. An aberrant expression of TGF-β1
receptor II (TGFRII) has been reported in the brain
of Alzheimer’s disease (AD) patients [14-17]. Reduced
TGF-β1 signaling increases amyloid deposition and
neurodegeneration in transgenic AD mice [13]. The
role of TGF-β1 has been also investigated in several other
neurodegenerative diseases such as Amyotrophic Lateral
Sclerosis (ALS) [18], Parkinson disease (PD) and Prion dis-
eases [9]. Reduced levels of TGF-β1 in the brain increase
susceptibility to excitotoxic injury and neurodegeneration
in heterozygous TGF-β1 knockout mice [12].
Under normal conditions, the expression of TGF-β1
is minimal and drastically up-regulates under pathologic
circumstance, during which it plays a key role in the coord-
ination of inflammatory responses and tissues recovery
[19-21]. TGF-β1 is predominantly synthesized by neurons
and glial cells, within the CNS, and by platelets and mono-
cytes/macrophages in the peripheral tissues [22,23].
Macrophages display remarkable plasticity that enables
them to perform distinct and even opposing function,
such as release of either inflammatory or anti-inflammatory
cytokines and growth factors, in response to different envir-
onmental cues [24]. Depending on the activation state,
macrophages can be designed as either classical activated
(M1), with pro-inflammatory properties, or alternatively
activated (M2) cells, which mediate anti-inflammatory re-
sponse [25]. Under physiological condition, macrophages,
like glia, interact with their surroundings and provide
protective cytokines and neurotrophins. Upon insult, both
cell populations can become pathologically activated lead-
ing to neuro-inflammation, and/or neurodegeneration by
altering expression of many neurotrophic factors [26].
In this study, we demonstrated that changes of periph-
eral TGF-β1 levels in HD depend on the variation in
the percentage of TGF-β1-producing monocytes-derived
macrophages along disease course. The differential cap-
acity of macrophages to produce TGF-β1 reflects different
cell phenotypes during the disease. After an early pro-
inflammatory phenotype, macrophages switched towards
an anti-inflammatory profile with disease progression. Al-
though not completely elucidated, changes of nuclear
factor-κB (NF-κB)-p65 expression/regulation may likelyrepresent one of the molecular mechanisms governing
macrophages heterogeneity in HD.
Results
Abnormal levels of peripheral TGF-β1 in HD depend on
monocytic/macrophagic cell subset
In order to identify what peripheral cell population pri-
marily determined fluctuation of TGF-β1 levels in the
serum of HD patients we examined the contribution of
each whole blood cell subset at producing the cytokine
by flow cytometry analysis (FACs). We first demonstrated
similar absolute counts (n° cells ×103/ml) of whole blood
cell subsets (lymphocytes, monocytes and granulocytes)
in HD individuals (Table 1) and controls (Additional file 1).
Each cell subset was then examined to determine the rela-
tive contribution to TGF-β1 production. The percentage of
lymphocytes and granulocytes producing TGF-β1 was simi-
lar in HD individuals and healthy controls (Figure 1A, B).
Conversely, the percentage of TGF-β1-producing (TGF-
β1+) monocytes was markedly low in pre-manifested
(pre-HD) and clinical stage I subjects and gradually in-
creased in advanced-stage HD (HD) patients up to control
values (Figure 1C, Additional file 2). Analysis of TGF-β1
intracellular content, reported as mean fluorescence unit
(MFU), in TGF-β1+ cells, did not differ significantly among
all the groups (Figure 1D), suggesting no perturbation in
the synthesis of the neurotrophin. On the other hand,
immunoblotting analysis on total monocyte population
showed that TGF-β1 protein expression varied coherently
with the changes of the percentage of TGF-β1-producing
monocytes along disease stages (Additional file 3).
Similar to monocytes, monocytes-derived macrophages
from pre-HD subjects and clinical stage I patients showed
only a small portion of TGF-β1+ cells when compared to
cells derived from advanced HD stage patients and
controls (Figure 2A, Additional file 4). No difference
in the number of TGF-β1+ cells was detected between se-
vere symptomatic patients and normal control subjects
(Figure 2A), or between controls themselves (Additional
file 5). MFU values relating to macrophages were signifi-
cantly higher in pre-HD subjects as compared to controls
(Figure 2B), indicative of an increased expression of intra-
cellular TGF-β1 per cell at the early stage of the disease.
Consistently, analysis of gene expression showed a robust
increase of TGF-β1 mRNA levels in pre-HD compared ei-
ther with control subjects or more advanced HD patients
(Figure 2C). No difference in both MFU and TGF-β1 gene
expression was detected between later stage HD patients
and controls (Figure 2B,C).
Macrophages display different degrees of polarization
throughout HD course
In an attempt to investigate whether dynamic change
of TGF-β1-production during HD course was due to



























Pre-HD 14 35,4 ± 4,4 13 44,0 ± 2,4 - −13,8 ± 7,9 296,9 ± 70,8 99,7 ± 0,9 5,8 ± 4,3 278,3 ± 33,1 6,2 ± 6,9 25,0 ± 0,0 27,8 ± 1,3
(M = 8, F = 6)
I HD 15 (M= 9, F = 6) 46,9 ± 8,4 11,8 ± 1,1 44,1 ± 2,2 44,2 ± 8,1 −1,6 ± 6,2 389,5 ± 70,2 92,1 ± 4,1 24,1 ± 7,9 186,6 ± 54,1 16,5 ± 7,5 23,7 ± 1,7 26,9 ± 1,7
II HD 36 (M= 17, F = 19) 55,4 ± 10,9 7,7 ± 0,8 43,2 ± 3,0 47,1 ± 10,3 3,9 ± 10,3 403,8 ± 124,1 77,2 ± 6,3 39,3 ± 12,2 132,2 ± 52 19,7 ± 7,9 17,6 ± 4,2 23,3 ± 4,5
III HD 31 (M= 18, F = 13) 53,6 ± 11,7 4,6 ± 1,3 44,5 ± 3,5 44,1 ± 10,1 6,7 ± 6,7 448,8 ± 110,1 61,3 ± 11,6 55,4 ± 12,8 89,1 ± 48,8 23,4 ± 10,0 9,8 ± 5,1 20,2 ± 5,0
IV HD 10 (M= 4, F = 6) 59,2 ± 10,5 1,6 ± 0,5 44,0 ± 3,6 46,4 ± 10,2 11,7 ± 6,1 470,7 ± 128,0 39,0 ± 8,4 75,8 ± 21,4 71,2 ± 44,9 23,3 ± 14,2 1,3 ± 0,8 21,0 ± 5,1
V HD 6 (M = 2, F = 4) 58,3 ± 13,4 0 45,0 ± 5,3 41,0 ± 15,6 10,3 ± 5,9 499,5 ± 127,0 22,9 ± 6,4 90,2 ± 13,4 - 15,0 ± 6,0 0,2 ± 0,4 11,4 ± 3,0
Control subjects are 46 (M = 19, F = 27; mean age: 49,3 ±10,7). Values are given as mean ± s.d.
yrs: years; TFC: total functional capacity; AO: age at onset; HD DI: Huntington Disease Development Index; DB: Disease Burden; DS: Diasability.


















Figure 1 pre-HD subjects and stage I HD patients showed lower percentage of TGF-β1-producing (TGF-β1+) monocytes compared to healthy
control subjects and late stage HD patients. A and B, Bar histograms showing the percentage of TGF-β1-producing lymphocytes and granulocytes
in HD individuals (grey bars) and healthy control subjects (white bar). C, Bar histograms showing reduced percentage of TGF-β1+ monocytes in
pre-manifested (pre-HD) subjects and stage I HD patients with respect to healthy controls (CTRL) and late stage HD patients (HD). D, Bar histograms
showing similar intracellular TGF-β1 content (MFU) in monocytes from HD individuals (grey bars) and healthy control subjects (white bar). Data are
shown as mean ± s.d. * p < 0.05 ** p < 0.001 (ANOVA, Tukey post-hoc test).
Di Pardo et al. Molecular Brain 2013, 6:55 Page 4 of 14
http://www.molecularbrain.com/content/6/1/55a phenotypic heterogeneity of macrophagic cells, we
explored cell surface markers associated with either M1
or M2 phenotypes in monocyte-derived macrophages
from HD individuals and healthy controls. Pre-HD sub-
jects and clinical I stage HD patients showed a preferen-
tial pro-inflammatory M1 phenotype, - high percentage
of CCR2+CX3CR1- cells- and low percentage of CCR2-
CX3CR1+ cells (Figure 3A). Macrophages from HD patients
in the late stage of the disease, displayed changes in the ex-
pression of surface markers in favour of anti-inflammatory
M2 phenotype - high frequency of CCR2-CX3CR1+ cells –
and low percentage of CCR2+CX3CR1- cells (Figure 3B).
Expression of M1 and M2 surface markers was further con-
firmed by RT-PCR (data not shown).
Macrophages phenotype can be identified based also
on the production of specific cytokines [27]. Consistent
with phenotypic heterogeneity of macrophages in HD,
we found that the percentage of pro-inflammatory IL-12-
producing (IL-12+) cells (M1) was significantly increased
early in the disease and returned to control values in the
late stages HD patients (Figure 3C). Reduction in the fre-
quency of IL-12+ cells in symptomatic HD patients, was as-
sociated with a concomitant increase in the percentage of
anti-inflammatory IL-10-producing (IL-10+) macrophages
(M2 phenotype) (Figure 3D). Despite such phenotypic di-
versity, however, the intracellular content of both IL-12
and IL-10 did not differ significantly among all the groups
(data not shown).NF-κB pathway contributes to macrophages
heterogeneity in HD
In order to clarify the possible molecular mechanism
underlying the differential pattern of macrophages acti-
vation along disease course, we investigated the potential
involvement of NF-κB in the promotion of distinct macro-
phage phenotypes. Analysis of protein expression indicated
that monocytes-derived macrophages from pre-HD sub-
jects displayed higher levels of NF-κB-p65 compared to
symptomatic HD patients (Figure 4A). No differences
were observed between healthy controls and symptomatic
HD patients (Figure 4A). Interestingly, immunohisto-
chemical staining for NF-κB-p65 in different graded post-
mortem brain tissues showed NF-κB-p65 expression
changing profile similar to that observed in periphery
(Figure 4B).
TGF-β1 levels in human HD post-mortem striatum change
with disease-stages
Immunohistochemical analysis in post-mortem human
brain striatum, obtained from HD subjects and healthy
controls, showed variation of the number of TGF-β1 im-
munoreactive cells during disease progression (Figure 5,
Table 2) with a changing profile similar to that observed
in the periphery. TGF-β1 immunoreactivity was first de-
tected in pathological grade II HD brain tissues and
gradually increased with disease severity reaching a peak
in grade III-IV HD brains (Figure 5A, B).
Figure 2 Percentage of TGF- β1+ macrophages was reduced in
pre-manifested subjects (pre-HD) and stage I HD patients.
A, Bar histograms showing reduced percentage of TGF-β1+
macrophages in pre-symptomatic (pre-HD) and stage I HD individuals
compared to healthy controls (CTRL) and late stage HD patients (HD).
B, Bar histograms showing increased intracellular TGF-β1 content, MFU,
in macrophages from HD individuals (grey bars) and healthy control
subjects (white bar). C, Bar histograms showing increased mRNA levels
of TGF-β1 in pre-HD subjects compared to healthy controls (CTRL) and
HD patients. Data are shown as mean ± s.d. * p < 0.05 ** p < 0.001
(ANOVA, Tukey post-hoc test).
Figure 3 Macrophages displayed different degrees of polarization
during HD course. A and B, Bar histograms showing variable
percentage of CCR2+CX3CR1- (M1) and CCR2-CX3CR1+ (M2)
macrophages in pre-manifested subjects (pre-HD), severe HD patients
(HD) and healthy controls (CTRL). C and D, Bar histograms
showing changes in the percentage of IL-12 and IL-10 positive
macrophages in pre-manifested subjects (pre-HD), severe HD patients
(HD) and healthy control subjects (CTRL). C, IL-12-producing macro-
phages were increased in preHD subjects coherently with M1 pheno-
type. D, IL-10-producing macrophages were increased in HD patients,
consistently with changes of M2 phenotype. Data are shown as
mean ± s.d * p < 0.05 ** p < 0.001 (ANOVA, Tukey post-hoc test).
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In order to identify what cell population was primarily
implicated in the synthesis of TGF-β1 in brain tissues
along HD course, immunohistochemical studies were con-
ducted by using marker of specific cell types. First, we
investigated the involvement of microglia by using the
microglia-specific Ionized calcium-binding adaptor mol-
ecule 1 (Iba1). Our data showed no co-localization between
Iba1 and TGF-β1 immunopositive cells in none of the
neuropathological grades of HD brains (Additional file 6),
suggesting therefore, a poor implication of this cell type.
Conversely, analysis of Glial Fibrillary Acid Protein
(GFAP) immunoreactivity revealed a preferential impli-
cation of astrocytes in the synthesis of TGF-β1 in HD
brains (Figure 6). GFAP immunoreactive cells showed
co-localization with TGF-β1 positive cells starting from
grade II HD patients up to later grades (Figure 6).
Percentage of TGF-β1+ macrophages correlates with
clinical and genetic parameters
When we explored possible relationships between TGF-
β1 and clinical parameters, we observed a statistically
Figure 4 NF-κB -p65 protein expression is increased in macrophages from preHD subjects. A, Representative immunoblot (left) and
densitometric analysis (right) of NF-κB -p65 expression in healthy controls (CTRL, n = 5), pre-manifested subjects (pre-HD, n = 5) and severe HD
patients (HD, n = 5). Bars represent the mean values ± s.d *p < 0.05 (ANOVA, Tukey post-hoc test). B, Representative microphotographs showing
NF-κB -p65 immunoreactivity on formalin-fixed and paraffin-embedded post-mortem striatal tissues from control subjects (CTRL) and HD patients
at different neuropathological grades (Grade I, II, III, IV).
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TGF-β+ cells and age at onset (Figure 7A), disease burden
(Figure 7B), HD development index (Figure 7C), as well as
motor performance score (UHDRS1) (Figure 7D). A sig-
nificant negative correlation was also found with disabi-
lity scale (Figure 7E), functional test scores (UHDRS4)
(Figure 7F) and cognitive test scores (UHDRS2 and
MMSE) (Figure 7G, H). Instead, we did not find any corre-
lation between TGF-β1+ cells and the behavioural test
score (UHDRS3) (Figure 7I).Figure 5 Number of TGF-β1-producing cells in post-mortem brain tissue
microphotograph showing TGF-β1 immunoreactivity on formalin-fixed and pa
and HD patients at different neuropathological grades (Grade I, II, III, IV). B, Bar g
in HD brains. Data are presented as mean values ± s.d.Discussion
Changes in the levels and the activities of endogenous
neurotrophic factors are considered critical for the pro-
gression of degeneration in CNS diseases [28-30], in-
cluding HD [31]. Defective bioavailability of such factors
may have profound impact on the homeostasis of the
brain, affecting neuroplasticity and leading to neuronal
death [5]. Recently, we have reported dynamic variations
of TGF- β1 levels throughout the natural course of the
disease and argued that the defective bioavailability ofs increased with pathological grade in HD patients. A, Representative
raffin-embedded post-mortem striatal tissues from control subjects (CTRL)
raph showing semi-quantitative analysis of TGF-β1 immunoreactive cells
Table 2 Pathological and clinical data of three control
sublects and ten HD patients analysed for TGF-β1 expression
in the striatum post-mortem sample
Patients Age Gender Vonsattel
et al’s grade(years)
[67]
1 Healthy control 74 M CTRL
2 Healthy control 67 M CTRL
3 Healthy control 79 F CTRL
4 Symptomatic 69 M I
5 Symptomatic 50 M II
6 Symptomatic 58 M II
7 Symptomatic 69 M II
8 Symptomatic 53 M III
9 Symptomatic 56 M III
10 Symptomatic 53 M III
11 Symptomatic 47 F IV
12 Symptomatic 55 - IV
13 Symptomatic 49 F IV
CTRL = Healthy controls; I = early HD; II = light HD symptoms; III = moderate HD
symptoms; IV = strong HD symptoms.
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development of HD [10].
In the present study, we show that changes of periph-
eral TGF-β1 levels may be attributable to an aberrant
production by peripheral monocytes/macrophages. The
number of TGF-β1-producing cells varied with disease
progression and displayed a profile that was similar to
the pattern of TGF-β1 levels in the serum of HD pa-
tients [10]. Therefore, lower number of TGF-β1+ mono-
cytes/macrophages in pre-HD subjects, might potentially
explain the reduced bioavailability of TGF-β1 in the
serum of HD individuals at similar clinical stage. Both
peripheral monocytic and macrophagic cell subsets
from pre-HD subjects showed a significant reduction
of TGF-β1+ cells when compared to controls and late
stage HD patients. The lower percentage of TGF-β1+
monocytes-derived macrophages was associated with
an increased intracellular content of the cytokine in
pre-HD subjects and was accompanied by remarkable
increase in TGF-β1 gene expression, suggesting an attempt
of cells to counteract the early defective production of the
trophic factor.
Macrophages represent a heterogeneous cell popula-
tion that exhibits remarkably plasticity and can change
functional state in response to micro-environmental cues
[32]. Based on their activation state, macrophages can be
divided into two polarized phenotypes known as M1, or
“classical activated” and M2 or “alternative activated”
macrophages [25,33]. Identification of distinct macro-
phages subsets with divergent effects is based on theexpression of transcription factors, cell surface markers
that provide a mechanism for their differential recruit-
ment in response of different signal and production of
specific cytokines [27,34].
M1 macrophages, also designed as CCR2+CX3CR1-
cells, exhibit a typical inflammatory phenotype and secrete
high levels of pro-inflammatory cytokines including inter-
leukin (IL)-6 and IL-12. Conversely, M2 macrophages
or CCR2-CX3CR1+ cells exhibit anti-inflammatory and
tissue-repair function and proficiently produce high
amount of anti-inflammatory cytokines such as TGF-β1
and IL-10 [34-36].
Interestingly, a more detailed analysis of TGF-β1+
macrophages in HD revealed phenotypic heterogeneity
of these cells at different stages of the disease. In par-
ticular, we found that a large number of inflammatory
M1 macrophages dominated the early stage of the dis-
ease at the expenses of M2 macrophages; a phenomenon
that was reversed later, in symptomatic HD patients.
Moreover, analysis of the percentage of either IL-12 or
IL-10-producing cells further support macrophages het-
erogeneity in HD. IL-12+ macrophages were significantly
more numerous in pre-HD subjects than they were in
symptomatic HD patients, who instead showed a re-
markable increase of percentage of IL-10+ macrophages.
Changes in the percentage of both cytokines-producing
cells would explain the disease stage-dependent variation
of cytokines levels in HD individuals [2]. While in-
creased percentage of IL-12+ macrophages (M1) may ex-
plain the inflammation state in the early stage of the
disease, elevated IL-10 producing macrophages (M2) in
advanced disease stage may enhance an adaptive im-
mune response, convey neuroprotective signals and, pos-
sibly, outline a potential repairing attempt of tissues
in HD. Yet, the mechanisms that govern macrophage
polarization to different phenotypes remain to be de-
fined, however, our results suggest that it could be medi-
ated by a variable activity of NF-κB.
NF-κB is widely known for its role in the regulation of
inflammation and immune response [37]. It is an indu-
cible heteromeric transcription factor classically com-
posed of p50 and p65 subunits. While p65 possesses
a transactivation domain and modulates most of the
NF-κB’s transcriptional activity, p50 does not [38,39]. Ac-
tivation of NF-kB promotes M1 macrophage polarization
and turns inflammation processes on [40], while its in-
hibition results in switching the inflammation processes
off [41-43]. Dysregulation of NF-κB activity has been im-
plicated in the pathogenesis of multiple diseases such as
inflammatory diseases and neurodegenerative disorders
[44] including HD [45,46].
Here, we found that NF-κB pathway changed along HD
course in both central and peripheral district with similar
pattern. Unlike a relatively high expression of NF-κB -p65
Figure 6 Astrocytes are mainly involved in the synthesis of TGF-β1 in postmortem HD brains. Representative microphotographs of double
fluorescent staining for TGF-β1 and GFAP in post-mortem striatal tissues of control subjects and HD patients, showing co-localization between
GFAP and TGF-β1 immunoreactive cells at different pathological grades (from II to IV).
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NF-κB -p65 reduced compared to early HD subjects and
similar to healthy controls. Whether the reduction of
NF-κB -p65 in HD patients is due to its selective deg-
radation [47] or depends on anti-inflammatory strategy
that macrophages can adopt to counteract the overpro-
duction of inflammatory cytokines needs to be further
investigated. Predominance of classical NF-κB heterodi-
mer p50/p65 promotes M1 polarization, whereas M2
polarization is selectively mediated by p50/p50 homodi-
mers [38]. NF-κB-p50 plays a crucial role in the control
of M1-vs. M2-driven inflammation by selectively pro-
moting the production of the anti-inflammatory cytokine
IL-10 [48] that, in turns promotes the formation of p50/
p50 homodimer [49] and inhibits NF-κB activity [38].Based on this evidence, we hypothesized that the lower
availability of NF-κB -p65 late in the disease could cor-
relate with a preferential formation of p50/p50 homo-
dimers thereby driving anti-inflammatory IL-10 gene
transcription and subsequently favoring M1-M2 switch.
Further studies, however, are needed to address this
specific issue. Although little is known about the acqui-
sition and maintenance of M2 phenotype, we believe
that M1-M2 switch in HD, in all probability, points out
differential roles of peripheral immune cells in the dis-
ease induction or progression and may provide protec-
tion against overwhelming uncontrolled inflammation.
However the underlying molecular mechanism remains
to be elucidated. Ongoing studies in our laboratory
are examining whether and how mHtt can influence
Figure 7 (See legend on next page.)
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Figure 7 Percentage of TGF-β1+ macrophages correlates with clinical and genetic parameters in HD individuals. Linear regression analysis
showing positive correlation between percentage of TGF-β1+ cells and age at onset (A, n = 69), disease burden (B, n = 76), HD development index
(C, n = 79) and UHDRS1 (D, n = 72). Percentage of TGF- β1+ macrophages negatively correlates with disability scale (E, n = 74), UHDRS4 (F, n = 70),
UHDRS2 (G, n = 64), MMSE (H, n = 67). No correlation was observed between percentage of TGF-β1+ macrophages and UHDRS3 (I, n = 72). Each dot
represents a single subject.
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course.
Furthermore, similarly to the periphery, the ability of
cells to produce TGF-β1 in the brain varied during disease
course, indicative of a possible parallelism between periph-
eral dysfunction and central defects. TGF-β1 immunoreac-
tive cells were merely detectable in the pathological grade I
HD brains and increased dramatically with the severity of
pathological grades. TGF-β1 immunoreactivity was paral-
leled by a gradual increase in GFAP immunopositive react-
ive astrocytes, indicating a predominant role of these cells
to synthesize the neurotrophin in HD brains and highlight-
ing a spread reactive gliosis, a coordinated cellular response
usually aimed at mitigating damage to nearby neurons
[50]. A phenomenon this, which could be compared to
what occurs in periphery, where anti-inflammatory pattern
dominates the late clinical stage of the disease. Since the
biological effects of TGF-β1 are diverse, the pathological
significance of both clinical stage-dependent changes of
TGF-β1 content in periphery and pathological grade-
dependent changes in post-mortem brain tissues of HD pa-
tients is thought to be complex and, further studies are
needed to specifically address this issue.
Interestingly, changes in the TGF-β1+ macrophages
number correlated with HD clinical features, raising
the hypothesis that peripheral TGF-β1 may represent
a potentially valuable parameter for monitoring disease
development.
Conclusions
In summary our study suggests that alteration in mono-
cytes/macrophages homeostasis plays a critical role in
establishing the defective production of TGF-β1 in HD
and highlights an interesting parallelism between periph-
eral dysfunction and central defect. We believe that the
discovery of macrophages plasticity and an unbalanced
M1/M2 phenotype in HD point out a novel biological
process that could explain the variable inflammatory
profile in HD and eventually define the possible molecu-
lar mechanism underlying immune response in the dis-
ease. Macrophages heterogeneity in HD likely reflects
dynamic variation in the micro-environmental changes
during the transition from early to advanced HD stages,
which would result in progressive modulation of NF-κB
activity in macrophages and their subsequent conversion
from M1 to M2 phenotype.To our knowledge, this is the first evidence of a bio-
logical phenomenon never described before in HD. Un-
derstanding the biological mechanisms whereby each of
the macrophages subset is induced to assume these dif-
ferent roles may provide new opportunities to therapeut-
ically manipulate immune response in HD.
In conclusion, we believe that our study may be of
clinical relevance as it has the potential of leading to the
identification of possible indicator for predicting HD on-
set that could advance the design of clinical trials to
delay onset or slow progression in HD.
Methods
Subjects
A total of 112 HD subjects (14 pre-HD, 15 stage I, 36 II,
47 III-V), and 46 gender- and age-matched healthy con-
trols divided into 3 groups: 25–40, 41–55, and 55–
80 year-old were recruited. Subjects’ demographic, clinical
and genetic characteristics are reported in Table 1. Pre-HD
subjects had previously requested a pre-symptomatic gen-
etic test by entering a specific program whose protocol
was ethically approved [51]. All HD subjects revealed a
CAG repeat expansion mutation and all of them as well
as controls were required to sign an informed consent
before recruitment in the study. All human experiments
were performed in accordance with the Declaration of
Helsinki [52].
Control subjects with a suspect of cardiovascular, psy-
chiatric or neurodegenerative disorders other than HD,
were excluded from this study. Clinical examinations
were conducted using the Unified Huntington’s Disease
Rating Scale (UHDRS) to measure motor, cognitive, be-
havioural and general function [53] and the Mini-Mental
State Examination (MMSE) was used to screen general
cognitive function [53,54]. Pre-HD subjects included ei-
ther asymptomatic individuals (total motor score of < 5
in the UHDRS and cognitive and behavioural assess-
ment within the normality) or individuals with soft signs
(suspicious clinical features that were insufficient to war-
rant a diagnosis of HD) [55]. The patients’ age at onset
(AO) was retrospectively established by interviews to fam-
ily members regarding the first neurological manifesta-
tions [56], thus excluding, in this first study stage, subjects
showing severe cognitive and psychiatric abnormalities
that represented a permanent change from the normal
state [57]. The predicted years to manifest the disease
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mula described by Langbehn et al. (2004) [58]. To esti-
mate the progression of the pathological process from
pre-HD stage, we calculated the ‘HD development’ index
by combining the predicted years to onset for pre-HD
subjects and disease duration (years-from-onset) for
patients [59,60]. The disease burden (DB) index was
measured according to the previously described formula:
age x (CAG–35.5) [61]. The Disability Scale (DS) com-
bines patients’ independence and motor performance,
thus taking into account the subjects’ independence on
neurological motor impairment [62]. The disease stage




Peripheral blood mononuclear cells (PBMCs) were ob-
tained by density gradient centrifugation (Ficoll–Hypaque)
from freshly drawn venous blood (platelet-free). The cell
pellet was layered on a Percoll (GE Healthcare) gradient
and the interphase containing monocytic cells was ob-
tained following a 800 g centrifugation [64]. After washing
monocytes were seeded into 24-well plates culture contain-
ing RPMI (Sigma, San Louis, MO, USA) supplemented
with 10% heat inactivated foetal bovine serum (FBS),
2 mM L-glutamine and 100 μg/ml streptomycin and
100 units/ml penicillin. Cells were maintained for 7 days at
37°C in a humidified atmosphere containing 5% CO2 and
cultured in presence of 100 ng/ml of macrophages colony
stimulating factor (M-CSF, GE-Healthcare) to obtain fully
differentiated macrophages [65].
Flow cytometry analysis
Adherent macrophagic cells were detached by vigorous
pipetting ice-cold phosphate buffered saline (PBS), cen-
trifuged at 200 × g for 5 minutes and washed with PBS.
Cell suspension was then fixed with 4% PFA and incubated
with FITC-conjugated anti-human CD80 (EuroBioSciences
GmbH, Germany) or an equivalent amount of isotypic
control IgG1 (EuroBioSciences GmbH, Germany) for 1 h.
CD80-positive macrophages were >90% gated cells (data
not shown). For the detection of intracellular cytokines,
cells were permeabilized with a buffer containing 0.1%
(w/v) tritonX-100, 0.05% (w/v) NaN3 in PBS, and incu-
bated for 1 h at room temperature with PE-conjugated
anti-human TGF-β1 or PE-conjugated anti-human IL-
10 or anti-human IL-12 (BD Pharmingen, San Jose, CA
USA) or an equivalent amount of IgG1 and IgG2a (BD
Pharmingen, San Jose, CA USA) isotypic controls, respect-
ively. Cells were washed and re-suspended with PBS before
acquisition. The cytokine-positive cells and the relative
mean fluorescence unit (MFU) were scored on the basis of
isotype controls.Real-time RT-PCR analysis
TGF-β1 gene expression in macrophages from pre-HD
subjects, HD patients and healthy controls, was mea-
sured by quantitative PCR analysis performed on a
StepOnePlus instrument (Applied Biosystems) by using
the following primer sequences: Fwd: 5′-CGAGCCT
GAGGCCGACTACTA-3′; Rev: 5′-CTCGGAGCTCTG
ATGTGTTGAA-3′. Briefly, total RNA was extracted
using RNeasy kit (Qiagen) according to the manufacturer’s
instructions and reverse transcribed using Superscript II
reverse transcriptase (Invitrogen) and oligo-d(T) primer.
Resulting cDNAs were amplified using Power SYBR Green
PCR Master Mix (Applied Biosystems) following the man-
ufacturers’ instructions. The level of each mRNA was
normalized to that of cyclophilin A (CypA). PCR cycling
parameters were as follows: 50°C for 2 min, 95°C for
5 min, followed by 40 cycles of 95°C for 20 s, 60°C for
1 min, and 72°C for 40 s.
Cell subsets from whole blood
Whole blood analyses were carried out in 81 HD individ-
uals (5 pre-HD subjects, 11 I HD, 36 II HD and 29 III-V
HD stage patients) and 26 gender- and age-matched
healthy controls. Venous blood drawings were collected
applying minimal venous stasis in order to minimize cell
activation. Whole blood (50 ml) for each sample was fixed
with PFA 2% over night at 4°C and circulating cell subsets
were distinguished from each other on the basis of physical
parameters by using forward (FSC-H, cell volume index)
and side light-scatter patterns (SSC-H, cell density index).
Cells were then labelled with FITC-conjugated anti-human
CD14 (BD Pharmingen, San Josè, CA USA) or equivalent
amount of isotypic control IgG2a, k (BD Pharmingen, San
Josè, CA USA) for the detection of monocytes. CD14-
positive monocytes were >90% gated cells (data not
shown). After washing with PBS, cells were permeabilized
with 0.3% tritonX-100 and incubated with PE-conjugated
anti-human TGF-β1 (R&D Systems, Minneapolis, MN
USA) or an equivalent amount of isotypic control IgG1
(R&D Systems, Minneapolis, MN USA). The percentage
of TGF-β1+ cells and the intracellular content of the
cytokine (MFU), were scored on the basis of isotype con-
trol. All the experiments were performed by using a
Becton-Dickinson FACS Calibur flow cytometer (BD, San
Josè, CA, USA).
Flow cytometry analysis of macrophage M1 and
M2 subsets
Analyses of macrophage subsets were carried out in 12
HD individuals (5 early HD subjects and 7 II-III HD
stage patients) and 5 gender and age-matched healthy
controls. After isolation and differentiation, detached
monocytes-derived macrophages were incubated with
FITC-conjugated anti-human CCR2 and with PE-conjugated
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control IgG2b and IgG1, respectively. Cells were incubated
for 45 minutes at 4°C in the dark, washed with PBS and
acquired to the cytometer. Macrophages were gated on
the basis of cells size (FSC-H) and cells density (SSC-H).
The percentage of M1 macrophages was identified as
CCR2 positive-CX3CR1 negative cells (CCR2+CX3CR1-)
while the percentage of M2 macrophages was identified as
CCR2 negative -CX3CR1 positive cells (CCR2- CX3CR1+)
on the basis of isotype controls. All antibodies were pur-
chased from R&D Systems (Minneapolis, MN USA). All
the experiments were performed by using a Becton-
Dickinson FACSCalibur flow cytometer (BD, San Josè,
CA, USA).
Immunoblotting
Monocytes-derived macrophages from pre-HD subjects,
symptomatic HD patients and controls were lysed in
lysis buffer containing 20 mM Tris, pH 7.4, 1% Nonidet
P-40, 1 mM EDTA, 20 mM NaF, 2 mM Na3V04, and
1:1000 protease inhibitor mixture (Sigma-Aldrich), soni-
cated with 2 × 10 s pulses and then centrifuged for
10 min at 10,000 × g. For analysis of NF-κB-p65 protein
levels, total protein lysate was immunoblotted with
anti-NF-κB-p65 (C-20) (1:500; Santa Cruz, sc-372).
Ponceau Red staining served as a loading control
[66]. TGF-β1 expression was determined by using
monoclonal anti- TGF-β1 (T0438) (1:1000; Sigma-
Aldrich). A goat polyclonal anti-Talin (C-20; Santa
Cruz, sc-7534) was used as loading control for
normalization. HRP-conjugated polyclonal secondary
antibody (GE-Healthcare) was used at 1:5000 dilution.
Protein bands were detected by ECL Prime (GE Health-
care) and quantitated with Quantity One (Bio-Rad
Laboratories) and/or ImageJ software.
TGF-β1 in human post-mortem brain samples
Post-mortem brain tissues from ten patients at different
pathological grades of HD [67] and three healthy controls
were examined in this study. Samples were obtained by
the New York Brain Bank at Columbia University, New
York, USA. Clinical and neuropathological data were sum-
marized in Table 2. Formalin fixed, paraffin-embedded
striatal tissues were sectioned at 10 mm. Deparaffinized
sections were soaked in 3% hydrogen peroxide to block
endogenous peroxidase activity. Sections were treated with
Pronase at 37°C for 10 min for antigen retrieval and incu-
bated overnight with monoclonal mouse anti-TGF-β1
antibody (1:1000; Chemicon, CA). TGF-β1 expression
was detected by incubating the sample for 1 hour
with secondary biotinylated anti-mouse antibody
(1:200; Vector Laboratories, Burlingame, CA). Visualization of
the immunoreaction was performed with 0.05% 3,3′-
diaminobenzidine tetrachloride (DAB) (ABC Elite kit;Vector Laboratories). Control staining was performed with-
out the specific primary antibody. Double fluorescence
immunohistochemistry was performed by incubating
brain sections over-night with polyclonal rabbit anti-TGF-
β1 antibody (1:100; Sigma-Aldrich) and monoclonal
mouse anti-GFAP (1:300; Sigma-Aldrich) or polyclonal
goat anti-Iba1 (1:2000; Abicam). Proteins were then visua-
lized after 1 hour of incubation with secondary Cy3 anti-
rabbit (1:200; Chemicon), and fluorescein anti-mouse
(1:100; Vector Laboratories) or biotin anti-goat (1:200;
Vector Laboratories) and fluorescein anti-biotin (1:100;
Vector Laboratories) antibodies.Statistical analysis
ANOVA followed by the Tukey’s multiple comparisons
test was used for the analysis of data with more than
two groups. Linear dependence of TGF-β1+ macro-
phages on Age at Onset (AO), Disease Burden (DB), Dis-
ability Scale (DS), Time from/to Onset (TO), UHDRS1, 2,
3, 4 scores and MMSE was determined by a simple
regression model. Data were considered statistically signifi-
cant at p < 0.05. Statistical analysis was performed with
Biostat2009 software.Additional files
Additional file 1: Total number of whole blood cells did not vary
between HD individuals and healthy controls. A-C, Bar histograms
showing total number of lymphocytic, granulocytic and monocytic cells
in both HD individuals (n = 81, gray bars) and healthy control subjects
(n = 26, white bar). Whole blood cell populations were distinguished from
each other on the basis of physical parameters by using forward (FSC-H,
cell volume index) and side light-scatter patterns (SSC-H, cell density
index). Cells number is expressed as n° cells × 103/ml. Data are shown as
mean ± s.d.
Additional file 2: Representative flow cytometric histograms showing
TGF-β1+ monocytes in control subject (CTRL), pre-manifested subject
(preHD) and stage HD patients (HD). TGF-β1+ cells were identified in
FL-2+ fluorescence scatter (black histogram). Isotype control (gray histogram)
was used to determine the 95% confidence interval of nonspecific
fluorescence.
Additional file 3: Immunoblotting analysis showing changes of
TGF-β1 expression at different disease stages. Representative
immunoblot (top) and densitometric analysis (bottom) of TGF-β1expression
in healthy controls (CTRL, n = 4), pre-manifested subjects (pre-HD, n = 4) and
severe HD patients (HD, n = 4). Bar graph represents the mean values ± s.d.
* p< 0.05 (ANOVA followed by Tukey’s multiple comparisons test).
Additional file 4: Representative flow cytometric histograms
showing TGF-β1+ macrophages in control subjects (CTRL),
pre-manifested subjects (pre-HD) and stage HD patients (HD).
TGF-β1+ cells were identified in FL-2+ fluorescence scatter (black histogram).
Isotype control (gray histogram) was used to determine the 95% confidence
interval of nonspecific fluorescence.
Additional file 5: Bar histograms showing no-age related changes
in the percentage of TGF-β1+ macrophages in control subjects. A,
Bar histograms showing percentage of TGF-β1+ macrophages in healthy
controls divided into age groups (25–40, 41–55, 56–80). B, Bar histograms
showing no changes of TGF-β1 content (MFU) in macrophages, from the
same control individuals. Data are shown as mean ± s.d.
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http://www.molecularbrain.com/content/6/1/55Additional file 6: Microglia appear not to be implicated in the
synthesis of TGF-β1 in post-mortem brain tissues along HD course.
Representative microphotographs of double fluorescent staining for TGF-β1
and Iba1 in post-mortem striatal tissues of control subjects (CTRL), and HD
patients at different pathological grades (from I to IV). No colocalization
between Iba1 immunoreactive cells and TGF-β1 immunopositive cells in
none of the pathologically graded brains was observed.
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